WBSCR19 Activators are a collection of chemical compounds that enhance the functional activity of WBSCR19 through diverse signal transduction mechanisms. Forskolin, Isoproterenol, Sildenafil, Vardenafil, Rolipram, and 8-Br-cAMP all work primarily by increasing intracellular cAMP levels, albeit through different mechanisms including direct activation of adenylate cyclase, inhibition of phosphodiesterase enzymes, or functioning as cAMP analogs. The elevated cAMP activates PKA, which in turn can phosphorylate and activate proteins that modulate WBSCR19 activity directly or indirectly. Ionomycin and A23187, acting as calcium ionophores, raise intracellular calcium levels, thus activating calcium-dependent kinases that could phosphorylate proteins associated with WBSCR19, thereby enhancing its activity. PMA, through the activation of PKC, and Chelerythrine, through the inhibition of PKC, demonstrate the intricate balance of kinases and phosphatases in regulating WBSCR19, where both activation and inhibition of PKC can result in the enhancement of WBSCR19's functional role, potentially by altering phosphorylation states of proteins within WBSCR19 signaling pathways.
Moreover, LY294002 and U0126 disrupt negative feedback loops and inhibitory phosphorylations within key signaling pathways like PI3K/Akt and MAPK/ERK, respectively, which can lead to the indirect enhancement of WBSCR19 activity. Forinstance, LY294002 inhibits PI3K, which may alleviate downstream inhibitory signals on proteins that interact with WBSCR19, while U0126 targets MEK1/2, potentially shifting the phosphorylation status in favor of proteins that activate WBSCR19. These activators collectively function by modulating key signaling molecules and pathways, thereby influencing the phosphorylation, localization, or conformation of proteins that associate with or regulate WBSCR19, resulting in its enhanced functional activity. This multipronged approach to activation underscores the complex regulation of WBSCR19 and highlights the potential for these diverse compounds to influence its activity through their targeted biochemical actions on the cellular signaling landscape.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to increased levels of cyclic AMP (cAMP) in cells. Elevated cAMP can enhance the activity of WBSCR19 by promoting protein kinase A (PKA) signaling, which can phosphorylate proteins that interact with or regulate WBSCR19. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that raises intracellular calcium levels. The increase in calcium can activate calmodulin-dependent kinase (CaMK), which may then phosphorylate and enhance the activity of WBSCR19 or its associated proteins. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which can lead to the phosphorylation of proteins that are part of the WBSCR19 signaling pathway, thereby enhancing WBSCR19 activity. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that increases cAMP levels via G protein-coupled receptor signaling, potentially enhancing WBSCR19 activity through cAMP-dependent pathways. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Similar to sildenafil, vardenafil inhibits PDE5 leading to increased cAMP and cGMP levels, which may enhance WBSCR19 activity through the same mechanism as sildenafil. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of PDE4, which degrades cAMP. By preventing cAMP breakdown, rolipram can enhance WBSCR19 activity through cAMP-dependent signaling pathways. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Br-cAMP is a cell-permeable analog of cAMP that activates PKA. By directly increasing PKA activity, 8-Br-cAMP can enhance WBSCR19 activity through phosphorylation of associated proteins. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as a calcium ionophore, similar to ionomycin, increasing intracellular calcium and potentially enhancing WBSCR19 activity through calcium-dependent signaling pathways. | ||||||
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is a PKC inhibitor that can indirectly enhance WBSCR19 activity by reducing PKC-mediated inhibitory phosphorylations that might negatively regulate WBSCR19. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can disrupt negative feedback loops within PI3K/Akt signaling, potentially leading to the enhancement of WBSCR19 activity by alleviating inhibitory signals. | ||||||